Biotechnology The China National Medical Products Administration (NMPA) has accepted for review the Biologics License Application (BLA) for sacituzumab govitecan-hziy (SG), an investigational therapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease, submitted by Chinese biotech Everest Medicines. 18 May 2021